Year None2022202120202019201820172014 Nov 22, 2022 PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference Nov 08, 2022 PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights Nov 04, 2022 PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors Aug 09, 2022 PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights Jul 18, 2022 PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors Jun 08, 2022 PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference Jun 07, 2022 PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation May 26, 2022 PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting May 10, 2022 PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights Apr 27, 2022 PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 14
